Dr. Agarwal's Health Care Limited has delivered exceptional financial performance for Q3FY26, with consolidated net profit surging 51% year-on-year to ₹337m compared to ₹223m in the corresponding quarter last year. The healthcare services company reported consolidated revenue of ₹5.3b versus ₹4.3b in the same period last year, marking robust operational growth.

Strong Quarterly Financial Performance

The company's Q3FY26 results demonstrate strong operational efficiency and profitability improvements. EBITDA reached ₹1.4b compared to ₹1.1b in the same quarter last year, with EBITDA margins expanding to 27.17% from 26.5% year-on-year, indicating improved operational leverage and cost management.

Nine Months Performance Highlights

For the nine months ended December 31, 2025, the company demonstrated exceptional growth momentum. Total income soared by 20.8% year-on-year to INR 1,548 Cr, while revenue from operations grew by 21.2% to INR 1,516 Cr. The company's profitability showed remarkable improvement with profit after tax growing by 74.3% to INR 118 Cr.

Operational Expansion and Network Growth

As of December 31, 2025, the company's network expanded to 272 facilities, with 14 new centers added during Q3FY26 comprising 9 secondary and 5 primary facilities. During the nine months period, 38 new centers were added including 1 tertiary, 22 secondary and 15 primary facilities. The company performed 81,002 surgeries in Q3FY26, showing an 11.2% year-on-year growth, while nine months surgeries reached 238,283, representing an 11.6% increase.

Board Meeting Decisions and Corporate Actions

The Board of Directors met on February 03, 2026, to approve several significant decisions beyond the quarterly results. The board approved the incorporation of a wholly owned subsidiary in Ethiopia through Orbit Healthcare Services (Mauritius) Limited, with an investment of 200,000 USD. Additionally, the board approved shifting the registered office from Buhari Towers to 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018, effective February 05, 2026.

Management Commentary

Dr. Adil Agarwal, CEO, commented on the strong performance: "The Company delivered a strong performance in Q3 FY26, marked by robust growth across revenues and profitability, reflecting sustained execution momentum. Revenue from Operations grew by 23.0% YoY to ₹530 Cr, driven by healthy patient volumes, strong traction across mature centres, and improving contribution from newer facilities."

The company remains focused on accelerating organic growth through aggressive greenfield expansion while maintaining high standards of patient safety and clinical quality. With 900+ doctors serving over 22 lakh patients during the nine months period, the company continues to strengthen its position as India's largest eye care service chain by revenue.

Dr. Agarwal's Health Care Limited has announced a promoter shareholding change through an inter-se transfer between promoter group members. The transaction involves the transfer of equity shares from Dr. Adil Agarwal to Dr. Amar Agarwal by way of gift, executed on December 31, 2025.

Share Transfer Details

The inter-se transfer involved 5,12,473 equity shares, representing 0.16% of the company's total share capital. This transaction was structured as a gift between promoter group members and falls under the regulatory framework of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Pattern Changes

Following the transaction, Dr. Amar Agarwal's shareholding in the company has increased from 4.29% to 4.46%. The change reflects an increase of 0.16% in his voting rights and overall stake in the healthcare company, while Dr. Adil Agarwal's shareholding decreased correspondingly.

Company Capital Structure

The company's equity share capital remains unchanged at ₹31.65 crores, consisting of 31,64,70,002 equity shares of Re. 1 each. The total diluted share capital also stands at the same level, indicating no outstanding convertible securities or warrants that could impact the shareholding calculations.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dr. Amar Agarwal submitted the required documentation to both the National Stock Exchange of India Limited and BSE Limited on January 2, 2026, ensuring full regulatory compliance for the inter-se transfer transaction.

The company's shares continue to be listed on both NSE and BSE, with the transfer not affecting the overall promoter group shareholding but only redistributing shares within the promoter group members.